Antidepressant shows promise for arthritis relief in new trial
NCT ID NCT06231745
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tested whether adding paroxetine, an antidepressant, to standard methotrexate therapy can better control rheumatoid arthritis. 100 adults with active RA took part. The main goal was to see if the combination lowers disease activity scores more than methotrexate alone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Paroxetine (an antidepressant) and methotrexate (a standard rheumatoid arthritis drug)
- What this could lead to
- If it works, this could offer a safe, affordable add-on treatment to better control rheumatoid arthritis symptoms.
- What could go wrong
- This is a small, completed trial with 100 participants, and paroxetine is not a standard RA treatment—results may not apply broadly or show clear benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mostafa Bahaa
Damietta, New Damietta, 34518, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new shoulder implant restore Pain-Free movement?
- Can a less invasive hip surgery speed up recovery?
- Which hip implant lasts longer? a Head-to-Head trial aims to find out
- Can pregnancy and neurological disease coexist safely? a new registry seeks answers
- Can group learning make biotherapy safer for arthritis patients?
- Can a specialized hand exercise protocol restore grip and ease pain in rheumatoid arthritis?